Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer's disease

M. Higuchi, H. Arai, T. Nakagawa, S. Higuchi, Taro Muramatsu, S. Matsushita, Y. I. Kosaka, M. Itoh, H. Sasaki

Research output: Contribution to journalArticle

Abstract

Twenty patients with Alzheimer's disease (AD) with defined apolipoprotein E (APOE), α1-antichymotrypsin (ACT) and presenilin-1 (PS-1) intronic genotypes were examined to quantify the regional cerebral metabolic rate of glucose (rCMRglc) by using positron emission tomography (PET) and 18F-2-fluoro-2-deoxy-D-glucose (FDG). The frontal rCMRglc was significantly increased in patients with the APOE ε4 allele in a dose-dependent fashion. In contrast, the temporo-parietal rCMRglc was significantly reduced in ACT type A allele (ACT*A) carriers compared with those in non-ACT*A carriers. The PS-1 type 1 intronic allele did not have any significant effects on rCMRglc in any cerebral region. These results suggest that both the APOE and ACT genes may play a distinct role in the progression of AD as monitored by imaging studies of cerebral glucose utilization.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalAlzheimer's Research
Volume4
Issue number1
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Apolipoprotein E4
Alzheimer Disease
Alleles
Glucose
Presenilin-1
Fluorodeoxyglucose F18
Apolipoproteins E
Positron-Emission Tomography
Genotype
apolipoprotein E1
Genes

Keywords

  • α-antichymotrypsin
  • Alzheimer's disease
  • Apolipoprotein E
  • Glucose metabolism
  • Positron emission tomography
  • Presenilin-1

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer's disease. / Higuchi, M.; Arai, H.; Nakagawa, T.; Higuchi, S.; Muramatsu, Taro; Matsushita, S.; Kosaka, Y. I.; Itoh, M.; Sasaki, H.

In: Alzheimer's Research, Vol. 4, No. 1, 1998, p. 33-38.

Research output: Contribution to journalArticle

Higuchi, M, Arai, H, Nakagawa, T, Higuchi, S, Muramatsu, T, Matsushita, S, Kosaka, YI, Itoh, M & Sasaki, H 1998, 'Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer's disease', Alzheimer's Research, vol. 4, no. 1, pp. 33-38.
Higuchi, M. ; Arai, H. ; Nakagawa, T. ; Higuchi, S. ; Muramatsu, Taro ; Matsushita, S. ; Kosaka, Y. I. ; Itoh, M. ; Sasaki, H. / Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer's disease. In: Alzheimer's Research. 1998 ; Vol. 4, No. 1. pp. 33-38.
@article{c79e12f3060e48519039fa4d3720d5c7,
title = "Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer's disease",
abstract = "Twenty patients with Alzheimer's disease (AD) with defined apolipoprotein E (APOE), α1-antichymotrypsin (ACT) and presenilin-1 (PS-1) intronic genotypes were examined to quantify the regional cerebral metabolic rate of glucose (rCMRglc) by using positron emission tomography (PET) and 18F-2-fluoro-2-deoxy-D-glucose (FDG). The frontal rCMRglc was significantly increased in patients with the APOE ε4 allele in a dose-dependent fashion. In contrast, the temporo-parietal rCMRglc was significantly reduced in ACT type A allele (ACT*A) carriers compared with those in non-ACT*A carriers. The PS-1 type 1 intronic allele did not have any significant effects on rCMRglc in any cerebral region. These results suggest that both the APOE and ACT genes may play a distinct role in the progression of AD as monitored by imaging studies of cerebral glucose utilization.",
keywords = "α-antichymotrypsin, Alzheimer's disease, Apolipoprotein E, Glucose metabolism, Positron emission tomography, Presenilin-1",
author = "M. Higuchi and H. Arai and T. Nakagawa and S. Higuchi and Taro Muramatsu and S. Matsushita and Kosaka, {Y. I.} and M. Itoh and H. Sasaki",
year = "1998",
language = "English",
volume = "4",
pages = "33--38",
journal = "Alzheimer's Research",
issn = "1356-918X",
publisher = "Rapid Science Publishers",
number = "1",

}

TY - JOUR

T1 - Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and α1-antichymotrypsin type A allele in Alzheimer's disease

AU - Higuchi, M.

AU - Arai, H.

AU - Nakagawa, T.

AU - Higuchi, S.

AU - Muramatsu, Taro

AU - Matsushita, S.

AU - Kosaka, Y. I.

AU - Itoh, M.

AU - Sasaki, H.

PY - 1998

Y1 - 1998

N2 - Twenty patients with Alzheimer's disease (AD) with defined apolipoprotein E (APOE), α1-antichymotrypsin (ACT) and presenilin-1 (PS-1) intronic genotypes were examined to quantify the regional cerebral metabolic rate of glucose (rCMRglc) by using positron emission tomography (PET) and 18F-2-fluoro-2-deoxy-D-glucose (FDG). The frontal rCMRglc was significantly increased in patients with the APOE ε4 allele in a dose-dependent fashion. In contrast, the temporo-parietal rCMRglc was significantly reduced in ACT type A allele (ACT*A) carriers compared with those in non-ACT*A carriers. The PS-1 type 1 intronic allele did not have any significant effects on rCMRglc in any cerebral region. These results suggest that both the APOE and ACT genes may play a distinct role in the progression of AD as monitored by imaging studies of cerebral glucose utilization.

AB - Twenty patients with Alzheimer's disease (AD) with defined apolipoprotein E (APOE), α1-antichymotrypsin (ACT) and presenilin-1 (PS-1) intronic genotypes were examined to quantify the regional cerebral metabolic rate of glucose (rCMRglc) by using positron emission tomography (PET) and 18F-2-fluoro-2-deoxy-D-glucose (FDG). The frontal rCMRglc was significantly increased in patients with the APOE ε4 allele in a dose-dependent fashion. In contrast, the temporo-parietal rCMRglc was significantly reduced in ACT type A allele (ACT*A) carriers compared with those in non-ACT*A carriers. The PS-1 type 1 intronic allele did not have any significant effects on rCMRglc in any cerebral region. These results suggest that both the APOE and ACT genes may play a distinct role in the progression of AD as monitored by imaging studies of cerebral glucose utilization.

KW - α-antichymotrypsin

KW - Alzheimer's disease

KW - Apolipoprotein E

KW - Glucose metabolism

KW - Positron emission tomography

KW - Presenilin-1

UR - http://www.scopus.com/inward/record.url?scp=0031911804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031911804&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031911804

VL - 4

SP - 33

EP - 38

JO - Alzheimer's Research

JF - Alzheimer's Research

SN - 1356-918X

IS - 1

ER -